Last reviewed · How we verify

Amenorrhea Secondary to Ovarian Dysfunction — Treatment Landscape & Competitive Intelligence

Amenorrhea Secondary to Ovarian Dysfunction (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Amenorrhea Secondary to Ovarian Dysfunction, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Endometrin progesterone Ferring Progesterone [EPC] Corticosteroid-binding globulin, Sodium/nucleoside cotransporter 1, Cation channel sperm-associated protein 1
Progesteron Progesteron Minia University Corticosteroid-binding globulin, Sodium/nucleoside cotransporter 1, Cation channel sperm-associated protein 1

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Ferring · 1 drug in Amenorrhea Secondary to Ovarian Dysfunction
  2. Minia University · 1 drug in Amenorrhea Secondary to Ovarian Dysfunction

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Amenorrhea Secondary to Ovarian Dysfunction:

Cite this brief

Drug Landscape (2026). Amenorrhea Secondary to Ovarian Dysfunction — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/amenorrhea-secondary-to-ovarian-dysfunction. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing